CClinicalTrials.gg
Sign In
Not yet recruitingNCT06607653Updated Sep 23, 2024

The Efficacy of Olfactory Training Intervention on Olfactory and Other Non-motor Symptoms in PD

An interventional study of Olfactory training in Parkinson Disease, Olfactory Disorder and Olfactory Training, sponsored by Anhui Medical University. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-23.

Sponsored by Anhui Medical University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

To explore the efficacy of olfactory training on olfactory and other non-motor symptoms in PD.

02

Conditions studied

  • Parkinson Disease
  • Olfactory Disorder
  • Olfactory Training

Browse trials for

Keywords

  • Parkinson Disease
  • Olfactory Disorder
  • Olfactory training
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Anhui Medical University is the lead sponsor of 102 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. PD was diagnosed according to the criteria of Movement Disorders and Parkinson Disease Group of Chinese Society of Neurology of Chinese Medical Association.
  2. Olfactory score was 1 standard deviation lower than the corresponding age norm;
  3. no medication plan in the past four weeks or no change in medication plan in the past four weeks, which can be maintained until the end of the experiment; 4.40-75 years old, with normal vision, hearing and language understanding and expression ability;

5.Good cooperation of patients

Exclusion criteria

Exclusion Criteria:

  1. Parkinson\'s syndrome and Parkinson\'s plus syndrome caused by cerebrovascular disease, encephalitis, trauma, drugs, etc.;
  2. Neuropsychiatric diseases that may affect the sense of smell, such as depression, anxiety, schizophrenia, etc.;
  3. History of nasal disease or surgery, such as rhinitis, sinusitis, nasal septum deviation, etc. Upper respiratory tract infection in the past 3 weeks;
  4. Long-term smoking and occupations that inhale chemical irritants for a long time.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    OT grroup

    Olfactory training used repeated stimulation of different olfactory substances at high concentrations, combined with odor association and odor identification training, twice in the morning and evening, each time for 5 minutes, for 15 weeks.

    Device: Olfactory training

  • No intervention
    No intervention group

    There were only pre-test and post-test without any intervention

Interventions

  • DeviceOlfactory training

    Olfactory training used repeated stimulation of different olfactory substances at high concentrations, combined with odor association and odor identification training, twice in the morning and evening, each time for 5 minutes, for 15 weeks.

06

What researchers measure

Primary outcomes

  1. Olfactory Function Test

    The olfactory test developed by the Institute of Psychology, Chinese Academy of Sciences was used to evaluate the olfactory ability, including threshold, discrimination, and recognition.

    Time frame: baseline;15 weeks

Secondary outcomes

  1. MoCA

    Time frame: baseline;15 weeks

  2. Pittsburgh sleep quality index

    Time frame: baseline;15 week

  3. HAMA

    Time frame: baseline;15week

  4. HAMD

    Time frame: baseline;15 week

07

Study locations

1 site
  • Cognitive Neuropsychology Lab Anhui Medical University
    Hefei, Anhui, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06607653
Lead sponsor
Anhui Medical University
Responsible party
WANG KAI (Head, Dept of Neurology & Medical Psychology, Director, Cognitive Neuropsychology Lab, PRC, Anhui Medical University) — Principal investigator
First posted
Sep 23, 2024
Start date
Sep 25, 2024 (estimated)
Primary completion
Mar 10, 2025 (estimated)
Completion
Apr 10, 2025 (estimated)
Last update
Sep 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Parkinson Disease→

Other studies from this sponsor

Anhui Medical University

Start the discussion